search
Back to results

Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With OPCs

Primary Purpose

Gingivitis

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Oligomeric Proanthocyanidins
Placebo
Sponsored by
University of Seville
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Gingivitis focused on measuring Oligomeric Proanthocyanidins, Periodontal Disease

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Subjects older than 18 years, male or female, good general health, a minimum of 20 teeth (teeth that have gross caries, were crowned or extensively restored, orthodontic banded, abutments, or third molars were not included in the tooth count), signed informed consent before study initiation.

Exclusion Criteria:

  • Periodontal disease, defined as 4 mm and / or positive bleeding on probing
  • Pregnant or breastfeeding
  • Subjects with fixed or removable prosthesis
  • Tumor pathology in oral cavity; Use of antibiotics during 2 months period prior to the start of the trial; Hypersensitivity to red fruits in general; Xerostomia; Active Smoker; Contagious-infectious pathologies; Pathology with severe systemic repercussions; Any other judgment of the investigator if he believes endangers or risk to the subject participant; Subjects with phenylketonuria or allergy to aspartame; Use of any oral hygiene product for the duration of the study.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Oligomeric Proanthocyanidins

    Placebo

    Arm Description

    90 mg exocian cran 408 plus 120mg Vitamin C, 1 tablet by mouth, every 24 hours for 21 days

    Similar organoleptic experimental arm,1 tablet by mouth, every 24 hours for 21 days

    Outcomes

    Primary Outcome Measures

    Silness and Löe index
    Six teeth were examined according to Ramfjord criteria (16-21-24-36-41-44 ). Four surfaces of each tooth were examined, making a total of 24 measurements taken.
    Gingival Bleeding index
    A periodontal probe was used to make this index. The values established for the examination are found below: 0 - Absence of inflammation. 1 - Mild inflammation, slight change in colour and no gingival edema. No bleeding on probing. 2 - Moderate inflammation, redness, edema and gingival hypertrophy. Bleeds to probe (after 10 seconds). 3 - Severe inflammation, marked redness and hypertrophy. There may be ulcerations. Tends to spontaneous bleeding.
    Turesky Plaque Index
    The buccal surfaces of anterior teeth were examined using a mouthwash of basic fuchsine as developing agent plaque and a numerical scoring system from O to 5 was established. 0: There is no plaque 1: Independent streaks of plaque in the cervical margin of the tooth. 2: thin continuous band of plaque (up to 1mm) at the cervical margin. 3: Band greater than one millimetre wide, but covers less than one third of the crown. 4: The plate covers third but not more than two thirds of the crown. 5: The plate covers two thirds or more of the crown.
    Inflammatory crevicular fluid study (IL6)
    Crevicular fluid samples were collected from interdental areas (lingual, buccal, mesial, and distal) of six teeth distributed by the four quadrants (16, 21, 24, 36, 41 and 44) by 5 strips of pressed paper 2cm long, especially for crevicular fluid. The impregnation time for each patient was 5 seconds and immediately inserted into 0.5ml Eppendorf microtubes with 50ul saline at 4 ° C for preservation. The sample transport to the biological laboratory was in a refrigerator, being stored frozen at -80°C at the laboratory until being processed.
    Brightness of the Gingiva
    The brightness of the gingiva was taken to identify possible changes in the gingival colour. The reddening of the gingiva accompanies the inflammation of the tissue, which is a factor that may help to differentiate inflammatory changes at this level. The luminosity of the gingiva was registered with Micro SpectroShadeTM MHT Optic Research AG. This instrument is designed for taking dental colour. However, besides including colour guides, the SpectroShadeTM has the ability to measure the brightness of any colour, not just shades of white. The change in the colour of the gingiva was observed within the same patient measuring the reference colour for each patient in the same point in each evaluation visit and being able to compare the change in the coloration of the same point.

    Secondary Outcome Measures

    Full Information

    First Posted
    July 30, 2015
    Last Updated
    August 4, 2015
    Sponsor
    University of Seville
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02515929
    Brief Title
    Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With OPCs
    Official Title
    Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With an Oligomeric Proanthocyanidins Nutritional Supplement
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2013 (undefined)
    Primary Completion Date
    December 2013 (Actual)
    Study Completion Date
    February 2014 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Seville

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Aim: To evaluate the effectiveness on tissue response of the new nutritional supplement made of Oligomeric Proanthocyanidins (OPCs) in induced gingivitis after 21 days of use. Material and Methods: A double-blind randomized controlled prospective clinical trial was carried out on 20 patients divided into an experimental group treated with the OPCs pill and a control group treated with placebo, after fulfilling the selection criteria. Patients had to come 4 times during the study to register the Silness and Loe and Gingival Bleeding index, plaque index, inflammatory crevicular fluid study (IL6) and changes in brightness of the gingiva. No complementary hygiene methods were allowed during the 21 days.
    Detailed Description
    Material and Methods Study Design and Population A randomized, double-blind, placebo-controlled, clinical trial of 21 days of duration was conducted among 20 volunteer students of Dentistry of the University of Sevilla. No previous studies have been found in the literature, so 20 subjects were determined for the pilot study to test our hypothesis. The study protocol was approved by the Ethics Committee of the University of Sevilla. Prior to participation, the purpose and procedures were fully explained to all patients and all participants gave written informed consent in accordance with Helsinki declaration. The study was designed, conducted, analysed and reported according to guidelines for Good Clinical Practice. The study was approved by the Clinical Trials.gov Protocol Registration and Results System with the number XXXXYY. The protocol can be accessed if necessary in ClinicalTrials.gov. The study was carried out between September 2013 until January 2104. The recruitment started on September and the Baseline date took place on October 2013. After the 21 days follow-up, data was treated obtaining the results on January 2014. At the pre-screening visit the Medical and Dental histories were taken and the screening was carried out base don the inclusion and exclusion criteria. Inclusion criteria were: subjects older than 18 years, male or female, good general health, a minimum of 20 teeth (teeth that have gross caries, were crowned or extensively restored, orthodontic banded, abutments, or third molars were not included in the tooth count), signed informed consent before study initiation. Exclusion criteria were as follows: Periodontal disease, defined as 4 mm and / or positive bleeding on probing; Pregnant or breastfeeding; Subjects with fixed or removable prosthesis; Tumor pathology in oral cavity; Use of antibiotics during 2 months period prior to the start of the trial; Hypersensitivity to red fruits in general; Xerostomia; Active Smoker; Contagious-infectious pathologies; Pathology with severe systemic repercussions; Any other judgment of the investigator if he believes endangers or risk to the subject participant; Subjects with phenylketonuria or allergy to aspartame; Use of any oral hygiene product for the duration of the study. A single examiner determined assessment of patient eligibility for the study and enrolment of patients into trial. Patients eligible for the study were individually randomly assigned to Oligomeric Proanthocyanidins Nutritional Supplement treatment or Placebo groups by an informatics programme by LACER S.A. The study was double-blind. The examiner and the patient did not know into which group were assigned. Results were treated by another examiner who knows which patients belonged to the experimental or placebo group. The masking process was established by a number assignation to each patient in the study, the treatment was externally the same to the patient and examiner to not allowed knowing to which group belonged. Patients had to take the experimental or placebo treatment each night after dinner and after rinse with water. The pill was maintained in the mouth until complete dissolution. Drink or eat was not allowed during 30 minutes after taking the treatment. The experimental treatment consisted on 90mg exocian cran 408 (equivalent to 36 mg OPC) and 120 mg of Vitamin C, while the placebo group was composed of the same organoleptic substance but free of active ingredients. Both were similar in appearance. At the baseline stage of the trial a tartar removal was carried out in each patient and enough medication for the entire study plus a patient diary and instructions for its correct fulfilment were given. Inflammatory crevicular fluid (IL6) and the brightness of the gingiva were registered. Two evaluation visits were performance on the day 14 and 21 after the baseline for an oral clinical examination and to register the Silness and Löe Index, the Gingival Bleeding index, the Turesky plaque index, inflammatory crevicular fluid study (IL6) and changes in brightness of the gingiva. Silness and Löe index Six teeth were examined according to Ramfjord criteria (16-21-24-36-41-44 ). Four surfaces of each tooth were examined, making a total of 24 measurements taken. These measurements were performance with a periodontal probe by the same examiner. Gingival Bleeding index A periodontal probe was used to make this index. The values established for the examination are found below: 0 - Absence of inflammation. 1 - Mild inflammation, slight change in colour and no gingival edema. No bleeding on probing. 2 - Moderate inflammation, redness, edema and gingival hypertrophy. Bleeds to probe (after 10 seconds). 3 - Severe inflammation, marked redness and hypertrophy. There may be ulcerations. Tends to spontaneous bleeding. Turesky Plaque Index The buccal surfaces of anterior teeth were examined using a mouthwash of basic fuchsine as developing agent plaque and a numerical scoring system from O to 5 was established. 0: There is no plaque 1: Independent streaks of plaque in the cervical margin of the tooth. 2: thin continuous band of plaque (up to 1mm) at the cervical margin. 3: Band greater than one millimetre wide, but covers less than one third of the crown. 4: The plate covers third but not more than two thirds of the crown. 5: The plate covers two thirds or more of the crown. Inflammatory crevicular fluid study (IL6) Crevicular fluid samples were collected from interdental areas (lingual, buccal, mesial, and distal) of six teeth distributed by the four quadrants (16, 21, 24, 36, 41 and 44) by 5 strips of pressed paper 2cm long, especially for crevicular fluid. The impregnation time for each patient was 5 seconds and immediately inserted into 0.5ml Eppendorf microtubes with 50ul saline at 4 ° C for preservation. The sample transport to the biological laboratory was in a refrigerator, being stored frozen at -80°C at the laboratory until being processed. Then the investigator sproceeded to analyse the concentration (pg/ml) of interleukins 6 present in each sample using panels 96 well bioplex brand Luminex®. Brightness of the Gingiva The brightness of the gingiva was taken to identify possible changes in the gingival colour. The reddening of the gingiva accompanies the inflammation of the tissue, which is a factor that may help to differentiate inflammatory changes at this level. The luminosity of the gingiva was registered with Micro SpectroShadeTM MHT Optic Research AG. This instrument is designed for taking dental colour. However, besides including colour guides, the SpectroShadeTM has the ability to measure the brightness of any colour, not just shades of white. The change in the colour of the gingiva was observed within the same patient measuring the reference colour for each patient in the same point in each evaluation visit and being able to compare the change in the coloration of the same point. Statistical Data Treatment The management of the data was performed using the SPSS statistical program. A similar database to Notebook Data Collection was created. For each variable a minimum and maximum range and the name of the variable and its values defined. The data are presented as the mean ± standard deviation of the measurements, and a p-value less than 0.05 was considered statistically significant. Chi-square test was performed to qualitative variable, T-student to the quantitative variable, after the Kolmogorov Smirnov to assure the normality. This study was approved by The Ethical Committee, and all examinations and treatments were performed with the consent of the subjects and according to the guidelines Declaration of Helsinki.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gingivitis
    Keywords
    Oligomeric Proanthocyanidins, Periodontal Disease

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    20 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Oligomeric Proanthocyanidins
    Arm Type
    Experimental
    Arm Description
    90 mg exocian cran 408 plus 120mg Vitamin C, 1 tablet by mouth, every 24 hours for 21 days
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Similar organoleptic experimental arm,1 tablet by mouth, every 24 hours for 21 days
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Oligomeric Proanthocyanidins
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Silness and Löe index
    Description
    Six teeth were examined according to Ramfjord criteria (16-21-24-36-41-44 ). Four surfaces of each tooth were examined, making a total of 24 measurements taken.
    Time Frame
    21days
    Title
    Gingival Bleeding index
    Description
    A periodontal probe was used to make this index. The values established for the examination are found below: 0 - Absence of inflammation. 1 - Mild inflammation, slight change in colour and no gingival edema. No bleeding on probing. 2 - Moderate inflammation, redness, edema and gingival hypertrophy. Bleeds to probe (after 10 seconds). 3 - Severe inflammation, marked redness and hypertrophy. There may be ulcerations. Tends to spontaneous bleeding.
    Time Frame
    21 days
    Title
    Turesky Plaque Index
    Description
    The buccal surfaces of anterior teeth were examined using a mouthwash of basic fuchsine as developing agent plaque and a numerical scoring system from O to 5 was established. 0: There is no plaque 1: Independent streaks of plaque in the cervical margin of the tooth. 2: thin continuous band of plaque (up to 1mm) at the cervical margin. 3: Band greater than one millimetre wide, but covers less than one third of the crown. 4: The plate covers third but not more than two thirds of the crown. 5: The plate covers two thirds or more of the crown.
    Time Frame
    21 days
    Title
    Inflammatory crevicular fluid study (IL6)
    Description
    Crevicular fluid samples were collected from interdental areas (lingual, buccal, mesial, and distal) of six teeth distributed by the four quadrants (16, 21, 24, 36, 41 and 44) by 5 strips of pressed paper 2cm long, especially for crevicular fluid. The impregnation time for each patient was 5 seconds and immediately inserted into 0.5ml Eppendorf microtubes with 50ul saline at 4 ° C for preservation. The sample transport to the biological laboratory was in a refrigerator, being stored frozen at -80°C at the laboratory until being processed.
    Time Frame
    21 days
    Title
    Brightness of the Gingiva
    Description
    The brightness of the gingiva was taken to identify possible changes in the gingival colour. The reddening of the gingiva accompanies the inflammation of the tissue, which is a factor that may help to differentiate inflammatory changes at this level. The luminosity of the gingiva was registered with Micro SpectroShadeTM MHT Optic Research AG. This instrument is designed for taking dental colour. However, besides including colour guides, the SpectroShadeTM has the ability to measure the brightness of any colour, not just shades of white. The change in the colour of the gingiva was observed within the same patient measuring the reference colour for each patient in the same point in each evaluation visit and being able to compare the change in the coloration of the same point.
    Time Frame
    21 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Subjects older than 18 years, male or female, good general health, a minimum of 20 teeth (teeth that have gross caries, were crowned or extensively restored, orthodontic banded, abutments, or third molars were not included in the tooth count), signed informed consent before study initiation. Exclusion Criteria: Periodontal disease, defined as 4 mm and / or positive bleeding on probing Pregnant or breastfeeding Subjects with fixed or removable prosthesis Tumor pathology in oral cavity; Use of antibiotics during 2 months period prior to the start of the trial; Hypersensitivity to red fruits in general; Xerostomia; Active Smoker; Contagious-infectious pathologies; Pathology with severe systemic repercussions; Any other judgment of the investigator if he believes endangers or risk to the subject participant; Subjects with phenylketonuria or allergy to aspartame; Use of any oral hygiene product for the duration of the study.

    12. IPD Sharing Statement

    Learn more about this trial

    Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With OPCs

    We'll reach out to this number within 24 hrs